Research Article

Influence of the COVID-19 Pandemic on Quality of Life of Patients with Parkinson’s Disease

Dengjun Guo,1 Bing Han,1 Yuqiang Lu,1 Chenling Lv,1 Xiaoling Fang,1 Zhenzhong Zhang,1 Zhenguang Liu,2 and Xiaoping Wang3

1Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang 310012, China
2Xinhua Hospital, Shanghai Jiao tong University Medical School, Shanghai 200092, China
3Tongren Hospital, Shanghai Jiao Tong University Medical School, Shanghai 200336, China

Correspondence should be addressed to Xiaoping Wang; x_p_wang@sjtu.edu.cn

1. Introduction

In the past several months, the coronavirus disease (COVID-19) outbreak has largely changed the rhythm of human life and overwhelmed the healthcare systems of many countries [1]. Many provinces in China, including Zhejiang, Guangdong, and Hunan, successively launched first-class responses to major public health emergencies, after lockdown measures were imposed in Wuhan, Hubei Province, at 10 a.m. on January 23, 2020. Since then, especially between February and March 2020, people were asked to stay at home as much as possible and not travel outside without specific reasons. Each family was given two passes per week to go out to purchase food and other necessities. Each pass could only be used by one person. Furthermore, a health green code was required to be shown when people entered public places. The travel restriction order was enforced by the government aimed at preventing the spread of the virus and protecting people from infection. However, it also led to the stagnation of social and economic life. Hospitals began reducing outpatient services and limiting daily visits, greatly impacting routine diagnoses and treatments of some chronic diseases, including Parkinson’s disease (PD). In fact, the quality of life of patients with PD was seriously affected due to limited activity, inconvenience of acquiring prescriptions in hospitals, and concerns about COVID-19 infection. Of course, the difficulties of these patients would not last long. With the alleviation of COVID-19 epidemic in China, measures for epidemic prevention and control were gradually lifted from April 1, 2020. People could freely enter or leave public places.
when their body temperature was normal and their health code was green, rather than red or yellow.

During the COVID-19 pandemic, telemedicine has instantly transformed from a niche practice into the dominant means of providing care [2]. Doctors in China took great efforts to help their patients through telemedicine, which made telemedicine develop rapidly in this particular period [3].

To explore the influence of the COVID-19 epidemic on the quality of life of patients with PD and the importance of telemedicine for management of PD, we carried out an epidemiological survey involving 113 patients with PD from Xihu District, Hangzhou, Zhejiang.

2. Materials and Methods

2.1. General Materials. A total of 113 patients with PD were selected from Xihu District, Hangzhou, Zhejiang. The inclusion criteria for this study were as follows: (1) patients who met the Movement Disorder Society clinical diagnostic criteria of primary PD, (2) whose Hoehn Yahr stage was I–IV, and (3) who agreed to participate in the study. The exclusion criteria for the study were as follows: (1) patients with mental disorders or cognitive dysfunctions that seriously affected language expression, (2) those with secondary Parkinson’s syndrome, (3) those with other inherited degenerative diseases or Parkinson’s syndrome, and (4) those patients whose Hoehn Yahr stage was V.

2.2. Methods. During the epidemic prevention and control period (February 1 to March 31, 2020), the questionnaire survey method was adopted, following the principles of confidentiality and voluntary participation. The researchers conducted a detailed inquiry of the investigation content through several means of communication, such as face-to-face assessments, telephone visits, and social media software (WeChat or Tencent QQ). Then the patients filled out the questionnaires, including the “COVID-19 Questionnaire for PD Patients during the Period of Epidemic Prevention and Control” and the “39-item Parkinson’s Disease Questionnaire” (PDQ-39). During the phase of gradually lifting epidemic prevention and control measures (April 1 to April 30, 2020), patients with PD could get help from neurologists through telephone calls, messages, or videos sent by social media software (WeChat or Tencent QQ). All patients enrolled in this study had follow-up appointments, and the PDQ-39 forms were completed again. All scale assessments were performed in the “open” phase of patient care. The questionnaires were collected at the beginning of May in 2020.

The study protocol was approved by the ethics committee at the local hospital. All enrolled patients or participants (caregivers) filled out written informed consent to be involved in this research.

2.3. Statistical Methods. SPSS version 20.0 statistical software (SPSS, Inc., Chicago, IL, USA) was used to process the experimental data. The measurement data were expressed using mean ± standard deviation, and the count data were tested using the t-test. \( P < 0.05 \) was statistically significant.

3. Results

3.1. General Information and Questionnaire Results of Patients. Among all the patients, 66 were male and 47 were female; the age range was 51–86 years, the average age was 69.5 ± 7.8, the course of the disease was 10–216 months, and the average duration was 72.6 ± 9.3 months. Each patient needed to fill in one “COVID-19 Questionnaire for PD Patients during the Period of Epidemic Prevention and Control” and two PDQ-39 questionnaires. In this study, a total of 113 copies of “COVID-19 Questionnaire for PD Patients during the Period of Epidemic Prevention and Control” and PDQ-39 forms were distributed, and 108 copies were effectively recovered. The recovery rate was 95.6%. Table 1 shows the results of “COVID-19 Questionnaire for PD Patients during the Period of Epidemic Prevention and Control.”

3.2. Comparison of PDQ-39 Assessment Results between during and after Epidemic Prevention and Control. Comparison of all PDQ-39 domain outcomes between during and after epidemic prevention and control are shown in Table 2. Except for social support, the scores of mobility, activities of daily living, emotional well-being, stigma, cognition, communication, bodily discomfort, and total PDQ-39 scores during epidemic prevention and control were significantly higher than those after epidemic prevention and control \( (P < 0.001) \), indicating that the quality of life of patients with PD was significantly affected during the period of epidemic prevention and control.

3.3. Comparison of PDQ-39 Outcomes between during and after Epidemic Prevention and Control in Patients Who Could Easily Receive Doctor’s Guidance and Those Who Found It Difficult. According to the results of item 4 in Table 1, patients who responded with a “yes” were classified as the “easy to get doctor’s guidance” subgroup and those who responded with a “no” were classified as the “difficult to get doctor’s guidance” subgroup. Subsequently, we compared the difference of PDQ-39 scores between during and after the epidemic prevention and control in the two subgroups separately. As shown in Table 3, only the outcomes of mobility, activities of daily living, emotional well-being, and total PDQ-39 scores during epidemic prevention and control were significantly higher \( (P < 0.05) \) than those after epidemic prevention and control in the “easy to get doctor’s guidance” subgroup. Almost all domains, except for social support, showed significant differences in the “difficult to get doctor’s guidance” subgroup \( (P < 0.001) \).

3.4. Comparison of PDQ-39 Outcomes between during and after Epidemic Prevention and Control in Patients Who Changed Routine Medication and Those Who did Not.
Table 1: COVID-19 Questionnaire for PD Patients during the Period of Epidemic Prevention and Control.

| Questions                                                                 | Patients          |
|---------------------------------------------------------------------------|-------------------|
| 1. Do you know about the COVID-19 pandemic?                               | 100% (108)       |
| Yes                                                                       |                   |
| No                                                                        | 0% (0)            |
| 2. How did you find out about the COVID-19 pandemic?                      |                   |
| Television                                                               | 70.4% (76)       |
| Newspapers                                                               | 29.6% (32)       |
| Smart phone or other social media                                        | 50.0% (54)       |
| Family members                                                           | 72.2% (78)       |
| The community staff                                                      | 100% (108)       |
| Doctors                                                                  | 20.4% (22)       |
| 3. Which is the biggest problem you are facing due to the COVID-19 pandemic? |                   |
| Unable to consult a doctor                                               | 60.2% (65)       |
| Unable to procure supply of medication due to lockdown                    | 24.1% (26)       |
| Unable to go for walks due to lockdown                                    | 15.7% (17)       |
| 4. Could you get access to your doctor regularly?                        |                   |
| Yes                                                                       | 30.6% (33)       |
| No                                                                        | 69.4% (75)       |
| 5. What are the main ways for you to get advice from your doctor during the period of epidemic control? (choose one or two) |                   |
| Smart phone apps or other social media                                    | 50.0% (54)       |
| Family members or caregivers visit the Parkinson’s clinic instead of patients | 69.4% (75)       |
| Go to the PD clinic directly                                             | 19.4% (21)       |
| 6. Have you adjusted the daily medication routine due to lockdown?       |                   |
| Yes                                                                       | 79.6% (86)       |
| No                                                                        | 20.4% (22)       |
| 7. If 6 is a “yes,” why?                                                |                   |
| Insufficient reserve of drugs for PD                                      | 39.8% (43)       |
| Worsening of symptoms                                                    | 39.8% (43)       |
| 8. Have you experienced any new/worsening of symptoms following the onset of the COVID-19 pandemic? |                   |
| Yes                                                                       | 79.6% (86)       |
| No                                                                        | 20.4% (22)       |
| 9. If 8 is a “yes,” then in which aspects?                               |                   |
| Increased tremor                                                         | 39.8% (43)       |
| Increased stiffness                                                      | 60.2% (65)       |
| Increased slowness                                                       | 60.2% (65)       |
| Newly appearing or worsening of dyskinesia                               | 39.8% (43)       |
| Newly appearing or worsening of fluctuation of symptoms                  | 40.7% (44)       |
| Excessive fatigue                                                        | 29.6% (32)       |
| Feeling/appear stressed or anxious                                      | 79.6% (86)       |
| Feeling/appear depressed                                                 | 50.0% (54)       |
| Sleep disorders                                                          | 39.8% (43)       |
| Reduced appetite                                                         | 10.2% (11)       |
| Increased aches and pains (including any painful cramp or muscle spasm)  | 29.6% (32)       |

Table 2: Comparison of all PDQ-39 domain outcomes of 108 patients between during and after epidemic prevention and control.

| Variables                  | During epidemic prevention and control | After epidemic prevention and control | t value | Sig   |
|----------------------------|----------------------------------------|--------------------------------------|---------|-------|
| Mobility                   | 20.42 ± 3.37                           | 15.84 ± 3.37                         | 16.961  | P < 0.001 |
| ADL                        | 12.73 ± 2.36                           | 10.41 ± 2.61                         | 9.174   | P < 0.001 |
| Emotional well-being       | 12.51 ± 1.85                           | 9.93 ± 2.42                          | 11.691  | P < 0.001 |
| Stigma                     | 8.60 ± 1.84                            | 7.36 ± 2.01                          | 6.955   | P < 0.001 |
| Social support             | 6.32 ± 1.47                            | 6.06 ± 1.84                          | 1.915   | 0.058  |
| Cognition                  | 8.39 ± 1.98                            | 6.92 ± 2.07                          | 7.714   | P < 0.001 |
| Communication              | 5.95 ± 1.55                            | 5.08 ± 1.76                          | 4.480   | P < 0.001 |
| Bodily discomfort          | 6.36 ± 1.68                            | 4.38 ± 1.69                          | 10.345  | P < 0.001 |
| Total score                | 81.29 ± 9.09                           | 65.94 ± 8.70                         | 20.363  | P < 0.001 |
According to the results of item 6 in Table 1, 79.6% (86) of these patients changed routine medication during the epidemic prevention and control while the remaining 20.4% (22) did not. The difference of PDQ-39 scores for during and after the epidemic prevention and control of the two parts was compared separately. As shown in Table 4, almost all domains, except for social support, showed significant differences ($P < 0.001$) in patients who changed routine medication, while only the outcomes of mobility, activities of daily living, emotional well-being, and total PDQ-39 scores showed significant difference ($P < 0.05$) in patients who did not change routine medication.

### 4. Discussion

The COVID-19 outbreak is now a worldwide topic. Currently, more and more people get infected and the death toll continues to rise. Without question, the COVID-19 pandemic has altered the way we practice neurology and our management of patients with movement disorders worldwide [4].

As a common chronic disease, PD needs long-term comprehensive management [5]. At present, drug therapy is the main treatment to control the symptoms of PD, which means that patients with this disease need regular medication to consistently control the symptoms. However, the COVID-19 outbreak and the consequent restrictions on travel have disrupted regular visits for patients with PD [6]. During the epidemic prevention and control period (February 1 to March 31, 2020), some hospitals even closed the Parkinson’s clinics because of the pandemic, rendering it impossible for some Parkinson’s patients to see a doctor on time, as well as causing worry about being infected and having irregular visits to the hospital [7]. However, there is currently insufficient evidence showing that PD by itself increases the risk of COVID-19 [8]. In accordance with China’s medical security system, patients with PD could only purchase medication from hospitals with doctors’ prescriptions. If they are unable to visit the hospital on time, they may be forced to decrease or even stop the anti-PD drugs.

From this investigation, it is clear that the COVID-19 outbreak is widely known among patients, and the main channel for them to obtain relevant information is through the community staff. This reason is because the community staff are responsible for the transmission of information about the pandemic to the residents and the management of personnel in and out of the community.

For patients with PD, the biggest problem during the epidemic prevention and control period has been that they cannot receive the doctor’s guidance regularly. Most chose to go to the hospital with their family members or relatives, while some chose to contact their doctors using social media software (WeChat or Tencent QQ). Nevertheless, not all patients possess the ability to use social media on smartphones. Thus, a small number of patients have needed to visit the Parkinson’s clinic by themselves. This necessity entails a high risk of being infected. However, on the positive side, of all the 108 patients surveyed, no one was definitely diagnosed with COVID-19. This is probably because Hangzhou was not a seriously affected area.

Patients with PD could develop different degrees of cognitive dysfunction [9], which may affect their understanding of the epidemic management program, resulting in
anxiety, depression, or other emotional disorders. In addition, 79.6% of the patients did not receive their doctor’s guidance in time and adjusted the drug dosage by themselves for the reasons of either shortage of the drugs or aggravation of symptoms. Most of the patients believed that their symptoms were aggravated. Among these, anxiety and depression were the main symptoms. The aggravation of rigidity and tardiness were also obvious. Some patients even suffered movement complications, such as dyskinesia and gidity and tardiness were also obvious. Some patients even suffered movement complications, such as dyskinesia and symptom fluctuation, which may be related to unreasonable request.

As shown in the results, except for social support, the scores of mobility, activities of daily living, emotional well-being, stigma, cognition, communication, bodily discomfort, and total PDQ-39 scores during epidemic prevention and control were significantly higher than those after epidemic prevention and control, indicating that the quality of life of patients with PD was significantly affected during the period of epidemic prevention and control. The reason why the social support scores did not change significantly may be due to the family members of patients having more time to accompany them due to lockdown during the epidemic.

The results shown in Table 3 revealed that the quality of life of patients who had difficulty getting their doctor’s guidance was more susceptible during the period of epidemic prevention and control. In addition, results shown in Table 4 indicated that the quality of life of patients who changed their routine medication due to lockdown was even worse.

The COVID-19 epidemic and corresponding travel restriction orders have also changed the way neurologists work. The global lockdown has forced some neurologists to practice from their homes and find new ways to manage neurological patients remotely [10]. In China, the daily workload of doctors had been reduced due to lockdown, which may have given them more time to improve the management of patients with PD through telemedicine. Doctors tried hard to guide the adjustment of therapeutic regimen of their patients through telephone or social media software (WeChat or QQ).

Fortunately, with the end of the epidemic prevention and control, patients’ regular medical treatment was restored, and their quality of life improved rapidly. People’s lives have gradually returned to normal, but telemedicine has been retained because the experience during the epidemic has proved that it is a quite effective and efficient means to manage chronic diseases including PD [11]. Even after the COVID-19 emergency, telemedicine will be essential to streamline outpatient visits, while at the same time limiting costs [12].

### 5. Conclusions

This investigation shows that the lockdown during the epidemic will directly cause the aggravation of patients’ symptoms and the decline in their quality of life. The quality of life of patients who had difficulty getting their doctor’s guidance or those who changed their routine medication due to lockdown was even worse. Telemedicine is a quite effective and efficient means to manage chronic diseases including PD. It is suggested using social media (such as WeChat or Tencent QQ) for regular interactions and follow-up appointments if effective for patients with inconvenient medical treatment during the COVID-19 pandemic.

### Data Availability

The data are available from the corresponding author upon reasonable request.

---

**Table 4: Comparison of PDQ-39 outcomes between during and after epidemic prevention and control in patients who changed routine medication and those who did not.**

| Variables | During epidemic prevention and control | After epidemic prevention and control | t value | Sig |
|-----------|--------------------------------------|--------------------------------------|---------|-----|
| Mobility  | 20.80 ± 3.41                         | 15.74 ± 3.37                        | 17.33   | P < 0.001 |
| ADL       | 13.03 ± 2.29                         | 10.41 ± 2.44                        | 9.172   | P < 0.001 |
| Emotional well-being | 12.80 ± 1.79 | 9.84 ± 2.44 | 12.270 | P < 0.001 |
| Stigma    | 8.81 ± 1.85                          | 7.26 ± 1.98                         | 8.724   | P < 0.001 |
| Social support | 6.48 ± 1.45 | 6.20 ± 1.80 | 1.716   | 0.090 |
| Cognition | 8.62 ± 1.98                          | 6.85 ± 2.06                         | 9.107   | P < 0.001 |
| Communication | 6.10 ± 1.62 | 4.99 ± 1.74 | 5.095   | P < 0.001 |
| Bodily discomfort | 6.56 ± 1.65 | 4.13 ± 1.58 | 13.061  | P < 0.001 |
| Total score | 83.21 ± 8.43 | 65.41 ± 8.77 | 24.602  | P < 0.001 |

| Variables | During epidemic prevention and control | After epidemic prevention and control | t value | Sig |
|-----------|--------------------------------------|--------------------------------------|---------|-----|
| Mobility  | 18.91 ± 2.81                         | 16.73 ± 3.67                        | 4.446   | P < 0.001 |
| ADL       | 11.55 ± 2.30                         | 10.41 ± 3.25                        | 2.411   | 0.025 |
| Emotional well-being | 11.36 ± 1.62 | 10.27 ± 2.33 | 2.693   | 0.014 |
| Stigma    | 7.77 ± 1.57                          | 7.27 ± 2.00                         | 1.111   | 0.279 |
| Social support | 5.73 ± 1.45 | 5.50 ± 1.92 | 0.839   | 0.411 |
| Cognition | 7.50 ± 1.74                          | 7.18 ± 2.13                         | 0.656   | 0.519 |
| Communication | 5.36 ± 1.09 | 5.45 ± 1.82 | –0.253  | 0.803 |
| Bodily discomfort | 5.59 ± 1.59 | 5.36 ± 1.79 | 0.527   | 0.604 |
| Total score | 73.77 ± 7.68 | 68.18 ± 8.30 | 8.828   | P < 0.001 |

Data Availability

The data are available from the corresponding author upon reasonable request.
Conflicts of Interest
None of the authors have any financial disclosure to make or have any conflicts of interest.

Acknowledgments
The study was supported by the National key R&D Program of China (2017YFC1310300) and Public Welfare Project of Zhejiang Science and Technology Department (2017C33114).

References
[1] P. W. Tipton and Z. K. Wszolek, “What can Parkinson’s disease teach us about COVID-19?” Neurologia i Neurochirurgia Polska, vol. 54, no. 2, 2020.
[2] E. R. Dorsey, M. S. Okun, and B. R. Bloem, “Care, convenience, comfort, confidentiality, and contagion: the 5 C’s that will shape the future of telemedicine,” Journal of Parkinson’s Disease, vol. 10, no. 3, pp. 893–897, 2020.
[3] E. Cubo, A. Hassan, B. R. Bloem, and Z. Mari, “Implementation of telemedicine for urgent and ongoing healthcare for patients with Parkinson’s disease during the COVID-19 pandemic: new expectations for the future,” Journal of Parkinson’s Disease, vol. 10, no. 3, pp. 911–913, 2020.
[4] A. Bersano and L. Pantoni, “On being a neurologist in Italy at the time of the COVID-19 outbreak,” Neurology, vol. 94, no. 21, pp. 905–906, 2020.
[5] V. Cabreira, P. Soares-da-Silva, and J. Massano, “Contemporary options for the management of motor complications in Parkinson’s disease: updated clinical review,” Drugs, vol. 79, no. 6, pp. 593–608, 2019.
[6] B. Sennott, K. Woo, S. Hees et al., “Novel outreach program and practical strategies for patients with parkinsonism in the COVID-19 pandemic,” Journal of Parkinson’s Disease, 2020.
[7] R. C. Helmich and B. R. Bloem, “The impact of the COVID-19 pandemic on Parkinson’s disease: hidden sorrows and emerging opportunities,” Journal of Parkinson’s Disease, vol. 10, no. 2, pp. 351–354, 2020.
[8] S. M. Papa, P. Brundin, V. S. C. Fung et al., “Impact of the COVID-19 pandemic on Parkinson’s disease and movement disorders,” Movement Disorders, vol. 35, no. 5, pp. 711–715, 2020.
[9] X. Wang, X. Wang, X. Chen, S. Canning, X. Luo et al., “Cognitive changes and promotion in Parkinson’s disease,” Parkinson’s Disease, vol. 2018, pp. 1-2, 2018.
[10] E. Moro and H. H. Fernandez, “Adaptive neurology in COVID-19 times,” Parkinsonism & Related Disorders, vol. 75, pp. 124–125, 2020.
[11] R. Cilia, F. Mancini, B. R. Bloem, and R. Eleopra, “Telemedicine for parkinsonism: a two-step model based on the COVID-19 experience in Milan, Italy,” Parkinsonism & Related Disorders, vol. 75, pp. 130–132, 2020.
[12] G. Miele, G. Straccia, M. Moccia et al., “Telemedicine in Parkinson’s disease: how to ensure patient needs and continuity of care at the time of COVID-19 pandemic,” Telemedicine and e-Health, 2020.